[go: up one dir, main page]

TR200806300A2 - Çözünürlük artırıcı farmasötlk formulasyon - Google Patents

Çözünürlük artırıcı farmasötlk formulasyon

Info

Publication number
TR200806300A2
TR200806300A2 TR2008/06300A TR200806300A TR200806300A2 TR 200806300 A2 TR200806300 A2 TR 200806300A2 TR 2008/06300 A TR2008/06300 A TR 2008/06300A TR 200806300 A TR200806300 A TR 200806300A TR 200806300 A2 TR200806300 A2 TR 200806300A2
Authority
TR
Turkey
Prior art keywords
pharmaceutical formulation
solubility enhancing
enhancing pharmaceutical
solubility
combination
Prior art date
Application number
TR2008/06300A
Other languages
English (en)
Inventor
B�Lg�� Mahmut
Original Assignee
B�Lg�� Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B�Lg�� Mahmut filed Critical B�Lg�� Mahmut
Priority to TR2008/06300A priority Critical patent/TR200806300A2/tr
Priority to EP09741481A priority patent/EP2328563B1/en
Priority to PCT/TR2009/000108 priority patent/WO2010021608A1/en
Publication of TR200806300A2 publication Critical patent/TR200806300A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut buluş, çözünürlük sorunu olan bir aktif maddeyi diğer terapötik ajanlarla kombinasyon halinde içeren farmasötik formülasyonlara, bunların hazırlanma yöntemlerine ve tıbbi kullanımlarına ilişkindir.
TR2008/06300A 2008-08-22 2008-08-22 Çözünürlük artırıcı farmasötlk formulasyon TR200806300A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2008/06300A TR200806300A2 (tr) 2008-08-22 2008-08-22 Çözünürlük artırıcı farmasötlk formulasyon
EP09741481A EP2328563B1 (en) 2008-08-22 2009-08-24 Solubility enhancing pharmaceutical formulation
PCT/TR2009/000108 WO2010021608A1 (en) 2008-08-22 2009-08-24 Solubility enhancing pharmaceutical formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2008/06300A TR200806300A2 (tr) 2008-08-22 2008-08-22 Çözünürlük artırıcı farmasötlk formulasyon

Publications (1)

Publication Number Publication Date
TR200806300A2 true TR200806300A2 (tr) 2010-03-22

Family

ID=41396144

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2008/06300A TR200806300A2 (tr) 2008-08-22 2008-08-22 Çözünürlük artırıcı farmasötlk formulasyon

Country Status (3)

Country Link
EP (1) EP2328563B1 (tr)
TR (1) TR200806300A2 (tr)
WO (1) WO2010021608A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011002422A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
US9763885B2 (en) 2012-05-01 2017-09-19 Althera Laboratories Ltd. Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
US10376470B2 (en) 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
CN103784436B (zh) * 2014-02-27 2016-06-01 安徽联创生物医药股份有限公司 一种降脂复方制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1355644T1 (sl) * 2001-01-26 2006-10-31 Schering Corp Uporaba substituiranih azetidinonskih spojin za zdravljenje sitosterolemije
EP1653930B1 (en) * 2003-08-05 2007-12-19 Zentiva, a.s. Methods for the stabilization of atorvastatin
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2008101723A2 (en) * 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor

Also Published As

Publication number Publication date
WO2010021608A1 (en) 2010-02-25
EP2328563A1 (en) 2011-06-08
EP2328563B1 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
CY1123334T1 (el) Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης
TR201809514T4 (tr) Uzun süre etkili insülin formülasyonları.
TR200806298A2 (tr) Farmasötik formülasyon
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
UA105036C2 (uk) Амінотетралінові похідні, фармацевтична композиція, яка їх містить, і їх застосування в терапії
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
EA201390799A1 (ru) Триазолопиридины
TR200900878A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
TR201803451T4 (tr) Olmesartan formülasyonlari.
IN2014DN10134A (tr)
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
BR112015004115A2 (pt) composições farmacêuticas compreendendo flurbiprofeno
TR200900880A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
TR200806302A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
ATE530172T1 (de) Pharmazeutische formulierungen mit clopidogrel
TR201009399A2 (tr) Hızlı çözünen efervesan rosuvastatin formülasyonları.
TR200806299A2 (tr) Çözünürlük artırıcı farmasötik formülasyon
EA201590732A1 (ru) Диспергируемая таблетка